# Rhodobacter capsulatus PG Lipopolysaccharide As a Potential Blocker of Toll-like Receptor 2 and 4 Activation

## TL;DR

This study explores how a specific lipopolysaccharide from Rhodobacter capsulatus can block inflammation caused by bacterial infections.

## Contribution

The study identifies Rhodobacter capsulatus PG LPS as a potential blocker of TLR2 and TLR4 activation by bacterial agonists.

## Key findings

- Rhodobacter capsulatus PG LPS blocks cytokine synthesis triggered by TLR2 and TLR4 agonists.
- It suppresses TNF-α, IL-6, and IL-8 production in human whole blood cells.
- The LPS shows potential as a drug prototype against gram-negative and gram-positive bacteria.

## Abstract

TLR2 and TLR4 play a key role in the development of an inflammation in response
to a bacterial infection. We studied the effect of Rhodobacter
capsulatus PG lipopolysaccharide (LPS) on proinflammatory cytokine
synthesis activation by the TLR2 and TLR4 agonists E. coli
LPS, Streptococcus pyogenes lipoteichoic acid (LTA),
and Pam3CSK4 (a synthetic bacterial lipopeptide) in human whole blood cells.
Rhodobacter capsulatus PG LPS was shown to exhibit
antagonistic properties against the studied TLR4 and TLR2 agonists, blocking
the synthesis of the cytokines TNF-α, IL-6, and IL-8. Possible mechanisms
behind the suppressing effect of Rhodobacter capsulatus PG LPS
are proposed. Rhodobacter capsulatus PG LPS can serve as a
prototype for drugs against both gram-negative and gram-positive bacteria.